Brief: Unicycive Therapeutics, Inc. posts Q2 EPS USD -0.29
14/08/2023 23:23
Aug 14 (Reuters) - Unicycive Therapeutics, Inc. Q2 operating expenses USD 4.322 million. * Q2 income from operations USD -4.322 million * Q2 EPS USD -0.29 * Q2 net income USD -3.838 million
Recent news on Unicycive Therapeutics
See all newsBrief: Unicycive Therapeutics Appoints Meredith Manning To Board Of Directors
Brief: Unicycive Therapeutics Announces Resubmission Of New Drug Application For Oxylanthanum Carbonate
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
Unicycive rises on narrower quarterly loss